The research teams at LV Prasad Eye Institute under the Centre for Ocular Regeneration (CORE) at the Brien Holden Research Centre, organized the second edition of the ‘Future is Here’.

In recent transactions reported to the Securities and Exchange Commission, Gerhard Prante, a director at Cibus, Inc. (NASDAQ:CBUS), sold a total of 2,300 shares of the company's Class A Common Stock.

Robert F. Kennedy Jr., Trump’s pick to be health secretary, is keeping his financial stake in major vaccine litigation ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

While some mutations in the BRCA2 gene clearly indicate risks for breast and prostate cancer, thousands of less-common ...

The field of cancer research is rapidly evolving, with a growing focus on the intersection of cancer immunology, gene editing, and epigenetics. This ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

People genetically susceptible to Huntington's disease often see their movement, mood, and cognition decline slowly over time.

Scientists have completed construction of the final chromosome in the worlds' first synthetic yeast genome following more than a decade of work, opening new possibilities for creating resilient, ...

New research shows that female mice expressing only a maternal X chromosome experience faster brain aging and cognitive ...

Scientists from a collaboration of Australian research institutions have proposed that editing multiple genetic variants in ...

The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.